Research ExplorerPublicationsBrain Metastases in Patients With Germ Cell Tumors: Prognost...

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group

Standard

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. / Feldman, Darren R; Lorch, Anja; Kramar, Andrew; Albany, Costantine; Einhorn, Lawrence H; Giannatempo, Patrizia; Necchi, Andrea; Flechon, Aude; Boyle, Helen; Chung, Peter; Huddart, Robert A; Bokemeyer, Carsten; Tryakin, Alexey; Sava, Teodoro; Winquist, Eric William; De Giorgi, Ugo; Aparicio, Jorge; Sweeney, Christopher J; Cohn Cedermark, Gabriella; Beyer, Jörg; Powles, Thomas.

In: J CLIN ONCOL, Vol. 34, No. 4, 01.02.2016, p. 345-51.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Feldman, DR, Lorch, A, Kramar, A, Albany, C, Einhorn, LH, Giannatempo, P, Necchi, A, Flechon, A, Boyle, H, Chung, P, Huddart, RA, Bokemeyer, C, Tryakin, A, Sava, T, Winquist, EW, De Giorgi, U, Aparicio, J, Sweeney, CJ, Cohn Cedermark, G, Beyer, J & Powles, T 2016, 'Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group', J CLIN ONCOL, vol. 34, no. 4, pp. 345-51. https://doi.org/10.1200/JCO.2015.62.7000

APA

Feldman, D. R., Lorch, A., Kramar, A., Albany, C., Einhorn, L. H., Giannatempo, P., Necchi, A., Flechon, A., Boyle, H., Chung, P., Huddart, R. A., Bokemeyer, C., Tryakin, A., Sava, T., Winquist, E. W., De Giorgi, U., Aparicio, J., Sweeney, C. J., Cohn Cedermark, G., ... Powles, T. (2016). Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. J CLIN ONCOL, 34(4), 345-51. https://doi.org/10.1200/JCO.2015.62.7000

Vancouver

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. J CLIN ONCOL. 2016 Feb 1;34(4):345-51. https://doi.org/10.1200/JCO.2015.62.7000

Bibtex

@article{b988a440caaa4dd28b439b5d4c8dd1ba,
title = "Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group",
abstract = "PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT).PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point.RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001).CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.",
author = "Feldman, {Darren R} and Anja Lorch and Andrew Kramar and Costantine Albany and Einhorn, {Lawrence H} and Patrizia Giannatempo and Andrea Necchi and Aude Flechon and Helen Boyle and Peter Chung and Huddart, {Robert A} and Carsten Bokemeyer and Alexey Tryakin and Teodoro Sava and Winquist, {Eric William} and {De Giorgi}, Ugo and Jorge Aparicio and Sweeney, {Christopher J} and {Cohn Cedermark}, Gabriella and J{\"o}rg Beyer and Thomas Powles",
note = "{\textcopyright} 2015 by American Society of Clinical Oncology.",
year = "2016",
month = feb,
day = "1",
doi = "10.1200/JCO.2015.62.7000",
language = "English",
volume = "34",
pages = "345--51",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

RIS

TY - JOUR

T1 - Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group

AU - Feldman, Darren R

AU - Lorch, Anja

AU - Kramar, Andrew

AU - Albany, Costantine

AU - Einhorn, Lawrence H

AU - Giannatempo, Patrizia

AU - Necchi, Andrea

AU - Flechon, Aude

AU - Boyle, Helen

AU - Chung, Peter

AU - Huddart, Robert A

AU - Bokemeyer, Carsten

AU - Tryakin, Alexey

AU - Sava, Teodoro

AU - Winquist, Eric William

AU - De Giorgi, Ugo

AU - Aparicio, Jorge

AU - Sweeney, Christopher J

AU - Cohn Cedermark, Gabriella

AU - Beyer, Jörg

AU - Powles, Thomas

N1 - © 2015 by American Society of Clinical Oncology.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT).PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point.RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001).CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.

AB - PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT).PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point.RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001).CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.

U2 - 10.1200/JCO.2015.62.7000

DO - 10.1200/JCO.2015.62.7000

M3 - SCORING: Journal article

C2 - 26460295

VL - 34

SP - 345

EP - 351

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 4

ER -